- Interplay between polygenic effects and polypharmacy
- 2 on dementia: An investigation in an elderly Scottish
- 3 cohort.
- 4 Vasilis Raptis 1,2[†], Donncha Mullin 3,5, Sumbul Syed 6, Ian J Deary 4,7, Simon R
- 5 Cox^{4,7}, Tom C Russ^{3,5,7}, Michelle Luciano⁴
- ¹The Roslin Institute, College of Medicine and Veterinary Medicine, University of
- 8 Edinburgh

6

- ²Advanced Care Research Centre, School of Engineering, University of
- 10 Edinburgh
- ³Alzheimer Scotland Dementia Research Centre, University of Edinburgh
- 4Department of Psychology, University of Edinburgh
- ⁵Division of Psychiatry, Centre for Clinical Brain Sciences, University of
- 14 Edinburgh

- 15 °School of Health in Social Science, University of Edinburgh
- ⁷Lothian Birth Cohorts, University of Edinburgh
- [†] Corresponding author:
- 19 Vasilis Raptis
- 20 e-mail: V.Raptis@sms.ed.ac.uk

ABSTRACT INTRODUCTION: Polygenic Risk Scores for Alzheimer dementia (AD-PRS), a measure of aggregate AD genetic risk and polypharmacy have been associated with dementia. Here, we test their interaction's association with future dementia among older adults without baseline neurodegenerative diagnoses. METHODS: Using Cox proportional hazards and mortality-adjusted competing risk regression models we analysed up to 17.5 years all-cause incident dementia in the Lothian Birth Cohort 1936 (n=759, 105 dementia patients). We used polypharmacy (total or nervous-system-acting medications count), AD-PRS, and their interaction as main predictors. RESULTS: A non-significant interaction was found between AD-PRS and total polypharmacy (HR=1.06; p=0.15) or nervous-system-acting polypharmacy (HR=0.98; p=0.86) in shaping dementia risk. Omitting interaction, mortalityadjusted models showed significant AD-PRS prediction of dementia (HR ~1.40; p<0.001), non-significant total (HR=1.03; p=0.49), and nervous-system-acting polypharmacy effects (HR=1.27; p=0.069). DISCUSSION: Elucidating the complex interplay between polypharmacy and genetics could improve management of inappropriate medication in older adults genetically prone to dementia/AD. **KEYWORDS:** Alzheimer dementia. dementia, polygenic risk score, polypharmacy, longitudinal study, gene-environment interaction

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

1 BACKGROUND

44

45

Dementia, a condition describing the significant and progressive overall 46 47 deterioration of a person's cognition with consequent deterioration in function', is widely recognised to have multi-factorial causes, arising from the interplay 48 between environmental, lifestyle and genetic factors^{2,3}. 49 50 Alzheimer dementia (AD), the most frequent cause of dementia (accounting for 51 70 - 80% of dementia⁴) has been extensively shown to have a strong genetic component⁵⁻⁷. Multiple genetic variants have been identified as risk factors for 52 AD through large-scale Genome-Wide Association Studies (GWAS)^{5,6}. The most 53 unequivocally established AD risk gene is apolipoprotein E (APOE), located on 54 chromosome 19 8-11. Its coding protein, Apo-E, is an important cholesterol 55 56 carrying protein, implicated in several brain functions, including lipid transfer, injury repair, neuroinflammation and others. Notably, the APOE £4 allele confers 57 a dramatic increase in AD prevalence (4 to 10 fold increase) and lower age of 58 onset⁸, thus being considered an important genetic risk factor for AD. 59 60 Other smaller effect AD-associated genes have been implicated in multiple 61 biological processes, including microglia involvement, tau and amyloid-β protein 62 metabolism regulation, immunity, inflammation, cholesterol metabolism, and neurotransmitter regulation 12,13. To study the contribution of many genetic loci 63 64 with small effect, Polygenic Risk Scores (PRS) are often implemented, which estimate a single aggregate score for each individual that is indicative of their 65 genetic liability to a disease¹⁴. For AD, PRS calculated using many AD 66

associated genes have been found in several studies, with varying accuracy, to be predictive of AD risk, even without including the stronger APOE genetic effect^{5,6,10,11}. Furthermore, AD-PRS have been associated with cognitive impairment in older healthy adults, as well as several AD related neurodegeneration phenotypes (e.g. neuroimaging changes)¹². Although individuals' genetic variation is fixed at birth, genetic effects are thought to be modified through their interactions with environmental, lifestyle or social factors throughout life. Such gene by environment (GxE) interactions have been suggested in dementia and AD^{3,15}. Specifically for GxE interactions in dementia, it has been proposed that genetic risk for dementia can be mitigated by favourable modifiable lifestyle factors^{16–18} (i.e., healthy diet, physical activity, non-smoking, and low alcohol consumption), although with sometimes conflicting results 17. On the other hand, two randomised clinical trials 19,20 assessing the effect of multidomain lifestyle interventions on dementia found that APOE E4 allele carriers and non-carriers had similar results, indicating no APOE E4 interplay with lifestyle factors. However, most studies so far have focused only on APOE genetic variants for GxE interactions 16,18-20. Regarding AD-PRS interaction with the environment / lifestyle in shaping dementia or AD risk, less work has been done. In a Chinese cohort study¹⁵. individuals living around higher residential greenness had lower chances of cognitive impairment, with the effect being increased in those having lower PRS genetic risk, although marginally significant. In another study, conducted on a large European cohort, adherence to a healthy lifestyle did not significantly interact with AD PRS in shaping dementia risk².

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

Polypharmacy, a term indicating that someone takes multiple medications, is highly prevalent in older adults with multiple chronic conditions^{21,22}. It has been demonstrated that polypharmacy is associated with unfavourable outcomes, such as increased frequency of falls, increased hospitalisation and hospital readmission, adverse drug reactions and increased mortality^{21,23}. Harmful polypharmacy effects may arise due to drug-drug and drug-disease interactions, especially in older people who have a reduced ability to metabolise drugs²⁴. Specifically for dementia, the role of polypharmacy as a risk factor is less known²⁵. It has been estimated that polypharmacy burden is higher than the general population, given the higher number of comorbid physical conditions in dementia patients^{22,26}, and polypharmacy in people with dementia has been associated with increased emergency hospitalisation and mortality²⁷. Whether the effect of polypharmacy on dementia risk can be modulated by genetic factors is not known. In the present study, it is hypothesised that individuals exposed to polypharmacy have an increased dementia risk if they also have a high genetic risk profile, compared to individuals with a low genetic risk profile. This hypothesis is based on the idea that biological pathways which may be disrupted by drug-disease and drug-drug interactions are also affected by the genetic variants that lead to dementia pathology. For example, anticholinergic drugs, acting on acetylcholine neurotransmitters, have been found to increase dementia risk, adverse outcomes, and are frequent in dementia patients with polypharmacy^{22,28}. At the same time, acetylcholine neurotransmission-related genes (e.g. RAB10 gene) have been linked with AD pathogenesis¹³. In this study, the proposed hypothesis is addressed in a longitudinal Scottish cohort of older

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

adults, who were relatively healthy and dementia-free at the baseline age of 70 years. Specifically, an interaction effect between Alzheimer Disease Polygenic Risk Scores and the number of (1) total and (2) nervous system active baseline drugs is tested in terms of predicting dementia up to 17.5 years of follow-up.

2 METHODS

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

2.1 Dataset description

The present analysis was conducted on the Lothian Birth Cohort 1936 (LBC1936) dataset²⁹. This is a longitudinal study, designed as a follow-up to the Scottish Mental Survey of 1947 (SMS1947), an intelligence test conducted on pupils aged 11 years old across Scotland³⁰. From 2004 to 2007, LBC1936 recruited 1,091 participants of the SMS1947, then aged around 70 years old, and mostly living in Lothian at that time²⁹. Since it focussed on 'normal' cognitive ageing initially, no participants had a diagnosis of dementia at baseline. After this first wave of recruitment, participants were re-invited to the study every three years (at mean ages: 73, 76, 79 and 82 years) for follow-up testing, termed Waves 1 to 5 respectively. Wave 6 has recently finished, but data is not yet available. At each wave, a wealth of data has been collected from questionnaires, blood tests, physical, medical and cognitive measurements. In addition, participants who have consented to do so, have been linked to their electronic health record to obtain further information about their health status (e.g., disease diagnoses, hospital Detailed descriptions of the LBC1936 have been previously reported^{29,31,32}. For this analysis, information from Wave 1 has been utilised,

regarding: participants' demographic characteristics, genetic data and self-reported medication usage and medical conditions. The analysis was conducted on 759 individuals (105 dementia patients, 654 controls) for whom complete genetic data (including *APOE* gene alleles) and ascertained dementia outcome as of August 2022 (see "Outcome: incident dementia" section) were available.

2.2 LBC1936 genetic data

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

During Wave 1 of the LBC1936, genome-wide genotyping and genotyping of the Apolipoprotein E variants ($\epsilon 2$, $\epsilon 3$, and $\epsilon 4$ alleles) was performed^{29,32} for 1.005 individuals. Genotyping of approximately 500,000 genetic variants across the genome (Single Nucleotide Polymorphisms, SNPs) was done using the Illumina Human610-Quadv1 chip³³. Furthermore, non-genotyped variants have been imputed based on the Haplotype Reference Consortium³⁴ reference panel. totalling 39 million SNPs. High quality SNPs and individuals were extracted, in order to minimise genotyping and imputation errors and reduce the chance of biased results³⁵. The quality control filters applied on genotyped data were described in Houlihan et al, 2010³³. In brief theyincluded the following: One of each related pair of individuals (> 2nd degree relatives, i.e., half-siblings) were excluded (n=8); 1 individual with mostly non-European descent was excluded; 12 individuals whose reported and genetically inferred sex did not match (likely indicative of errors during genotype sample preparation) were excluded, and; SNPs that were missing from more than 2% of the individuals were excluded. For the present analysis, and on the genotyped and imputed data: 4,360,232 SNPs whose alleles were found in a frequency less than 1% in the cohort were excluded; 55 SNPs that deviated significantly from Hardy-Weinberg Equilibrium were excluded, and; 27.7 million imputed variants with an imputation score less than 0.8 were excluded. These quality control filtering steps were performed using the PLINK(v1.9) software^{36,37}. 799 individuals remained after quality control, containing approximately 7 million SNPs. 759 individuals formed the final sample for the analysis, after individuals with missing values in the *APOE* predictor and the covariates were removed (see below).

2.3 Predictors

2.3.1 Polygenic risk scores

Polygenic Risk Scores (PRS) were used as a risk factor representing the aggregated genome-wide genetic effect contributing to AD. PRS are calculated for each individual as a sum of their genome-wide risk alleles, weighted by each allele's effect size to the outcome (here AD status)¹⁴. For AD-PRS calculation, the allele effect sizes were obtained from the largest to-date European GWAS on AD, totalling up to 85,934 AD patients (Bellenguez et al, 2022)⁵. AD was chosen, as this is the dementia sub-type for which the largest GWAS has been conducted, and the most frequent dementia sub-type in the general population and the present sample (48.6%, Supplementary Table 1).

The PRSice2 (v2.3.5) software³⁸ was used to calculate the AD-PRS. PRSice2 uses the "clumping and thresholding" technique¹⁴. This means that the total number of SNPs is thinned down to retain only SNPs that are independent from each other (clumping) and significantly associated with the outcome (thresholding). Furthermore, the *APOE* region (chromosome 19, base pair

44,000,000 to 46,500,000¹¹, in the human reference genome GRCh37 coordinates) was removed before the calculation of the AD-PRS (see "APOE ε4 alleles" section). Finally, AD-PRS were calculated for the 759 participants with non-missing data, using 981 genome-wide AD associated SNPs at a p-value threshold of < 0.0002.

2.3.2 APOE ε4 alleles

Given the strong effect of the *APOE* $\varepsilon 4$ polymorphisms on dementia, it has been suggested for genomic analyses to treat *APOE* polymorphisms independently as a separate predictor^{10,11}, as it can mask the effects of other genetic variants with weaker effects. The *APOE* $\varepsilon 4$ polymorphism is thus included as a separate risk factor in the present analysis, defined as the number of $\varepsilon 4$ alleles per individual (0, 1 or 2). Since 32 individuals did not have information on *APOE* status, they have been excluded from the analysis, as this is an important risk factor for dementia.

2.3.3 Polypharmacy

Polypharmacy was defined as the count of total or nervous system-acting drugs taken at baseline. Measurements were obtained using LBC1936 participants' medication data. For each wave of the LBC1936, medication data was based on participants' prescription cards which were brought to the assessment centre and further inspected by the testing team. Data includes prescribed drugs (in their brand name or their generic name), over-the-counter drugs and dietary supplements. To ensure consistency, (e.g., no spelling mistakes, multiple brand names referring to the same drug), we applied several pre-processing steps in

order to code each drug name according to the Anatomical Therapeutic Chemical (ATC) classification system³⁹. The ATC classification system classifies the active ingredient(s) of a drug in a 5-level hierarchical code, based on its acting organ/anatomical system and its therapeutic, pharmacological, or chemical properties. Specifically, using only medication data from Wave 1 of LBC1936, the preprocessing steps included: Drugs in their brand names were searched in the British National Formulary (BNF) (https://bnf.nice.org.uk/)⁴⁰ and substituted with their generic name. Drugs in their generic name were inspected and corrected for spelling mistakes, also using the BNF website. Subsequently, for each drug's generic name, its corresponding ATC code was retrieved from the ATC classification system's online searchable (https://www.whocc.no/atc ddd index/)³⁹. For drugs database multiple ATC codes (e.g., acting on more than one system), all available ATC codes were retrieved. The following entries were excluded from the analysis: Drugs that could not be assigned to an ATC code homeopathic substances diet supplements o vitamins. Additionally, it was deemed appropriate to exclude topically applied dermatological drugs and those with ophthalmic, otic or nasal routes of

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

administration, as they are unlikely to have a systemic effect and interact with pathways affected by AD related genes.

After these pre-processing steps were applied, a "general" polypharmacy variable was defined as the total number of drugs taken at Wave 1. Additionally, a nervous-system-specific polypharmacy variable was defined as the number of drugs acting on the central nervous system, based on the corresponding ATC code (code starting with "N0" ³⁹).

2.3.4 Other covariates

Apart from the PRS, *APOE* and polypharmacy variables, the following variables were included as covariates: sex, age, BMI, Scottish Index of Multiple Deprivation (SIMD) index, smoking status (non-, ex-, or current smoker), alcohol consumption status (yes or no), number of comorbidities (max 10). The number of comorbidities was calculated by summing the presence, at the time of Wave 1 assessment, of self-reported diseases among: high blood pressure, diabetes, high cholesterol, history of cardiovascular disease, stroke, neoplasia, arthritis, Parkinson's disease, thyroid disease, leg pain or other unspecified disease. Dates of death were identified via data linkage with the National Health Service Central Register, provided by National Records of Scotland. Participant deaths were flagged to the research team approximately every 12 weeks beginning at study baseline. Finally, to account for any residual genomic population stratification⁴¹, which could inflate the effect of the PRS, the 4 first genomic principal components of the individuals were included as covariates.

2.4 Outcome: incident dementia

In a recent endeavour (as described here 42,43), dementia outcomes have been ascertained for LBC1936 participants. Briefly, a multi-disciplinary team of clinical dementia experts provided consensus status for dementia and, when possible, dementia sub-types, for all consenting participants⁴². This process included a comprehensive review of participants' electronic health records and death certificates for the presence of dementia. Additionally, when deemed necessary, home visits to suspected dementia patients were conducted by a trained clinician. Finally, a consensus diagnostic review board of experts assessed the strength of evidence for each participant, and categorised each as having "probable", "possible", or "no" dementia, as well as each dementia subtype. The dementia and dementia subtype diagnoses were based on the International Classification of Diseases-11 criteria^{42,44}. Furthermore, the age of onset has been reported as the earliest age for which any diagnosis was reported. Age of onset spanned a time period from approximately one year after attending Wave 1 attendance until mid-August 2022, when the ascertainment process ended⁴². In the present analysis, only "probable" dementia diagnoses were considered, due to the lack of definite evidence for the assignment of a dementia diagnosis in participants with "possible" dementia⁴². The outcome used here was time-toonset, the time period between Wave 1 assessment until all cause (non-subtype specific) dementia diagnosis in 105 participants.

2.5 Statistical Analysis

The aim of the present study was to determine the effect of AD-PRS, baseline polypharmacy, and their interaction on incident dementia over up to 17.5 years of follow-up. Given the longitudinal nature of the outcome, Cox proportional hazards

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

(Cox PH) models⁴⁵ were implemented. This type of modelling investigates the association between multiple predictors and the time that passes until an outcome event occurs⁴⁶ (here dementia). In a further analysis, to account for the possible bias of individuals dying before exhibiting the main dementia outcome, the Fine-Gray competing risk model^{47,48} was used. This extension of the Cox proportional hazards model estimates the effect of a predictor on the outcome of interest (dementia), given that a competing event has not happened yet (death)⁴⁶. Mirroring the procedure from Mullin et al. (2023)⁴³, for both analyses the time-to-event outcome variables were calculated as the time passing between Wave 1 assessment and the earliest of the following: (1) dementia diagnosis, if the individual was ascertained for dementia, (2) the individual's death, if the participant had died while dementia-free, or (3) end of ascertainment, if the individual was dementia-free and alive at the end of ascertainment period (mid-August 2022). Statistical implemented using the predictors described previously ("Predictors" section), as well as the interaction between AD-PRS and the polypharmacy variables. The results of the models are in the form of Hazard Ratios (HR) with 95% confidence intervals (CI) for each tested predictor. A null model that included only PRS and polypharmacy main effects, without their interaction was also implemented. The statistical analysis for those models was the same as described above. As a sensitivity analysis, cox PH and competing risk models were also run using time to AD diagnosis as outcome (n=51), as described above for the all-cause dementia models.

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

All analyses were conducted using the R (v4.2.2) statistical software⁴⁹, and the packages "survival"⁵⁰ for Cox PH models and "cmprsk"⁴⁸ for competing risk models.

3 RESULTS

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

3.1 Sample characteristics

After genotyping data cleaning and exclusion of individuals with missing values, the analysis sample consisted of 759 individuals. 105 individuals (13.8%) were diagnosed with dementia up to 17.5 years after follow-up from Wave 1. 51 of these individuals (6.7%) had an Alzheimer dementia diagnosis. Participants' characteristics at Wave 1 for all tested covariates are presented in Table 1. Participants' mean age at Wave 1 was 69.5 (standard deviation=0.83) years, while the mean age-at-onset for dementia was 80.7 (3.7) years. The median time from baseline to dementia diagnosis for later patients was 11.8 years [interquartile range (IQR): 7.88-14.35]. 277 (49.5%) participants had passed away at the time of censoring, Regarding polypharmacy, 164 (21.6%) of participants took 5 to 10 drugs at the time of Wave 1 testing, while 14 (1.8%) took more than 10 drugs simultaneously (excessive polypharmacy) (Sup. Table 2 and Sup. Figure 3), with a maximum of 16 simultaneous drugs. The most abundant drugs by the anatomical system on which they act (according to the ATC classification system³⁹), were those acting on the gastrointestinal system / metabolism (346 individuals taking at least 1, 45.6%), cardiovascular system (388 individuals, 5.1%) and nervous system (321

individuals, 42.3%) (Sup. Table 2). In addition, individuals taking multiple medications acting on the same system are reported: 141 (18.6%) individuals taking 3 or more cardiovascular medications; 46 (6 %) individuals taking 3 or more gastrointestinal / metabolic medication; and 9 (1.2%) individuals with 3 or more nervous system active medications simultaneously (Table 1 and Sup. Table 2).

Table 1: Descriptive statistics of LBC1936 at Wave 1.

T		_		
Variable	Level	Mean (SD) ₃₃₅ or n (%)		
Sex	Male	392 (51.6) 336		
	Female	368 (48.4)		
Age (years)		69.5 (0.83) ³³⁷	Footn	
BMI (kg/m²)		27.8 (4.24)	ote:	
SIMD index		4709 (1836) 338		
Smoking status	Never	368 (48.5)	DMI	
•	Ex-Smoker	328 (43.2) 339	BMI:	
	Current	64 (8.4)	Pody	
Alcohol status	No	99 (13)	Body	
	Yes (current)	661 (87)	Mass	
Comorbidities index		3.1 (1.8)	IVIASS	
APOE ε4 count	0	531 (69.9) 342	Index;	
	1	212 (27.9) 342		
	2	17 (2.2) ₃₄₃	SD:	
No. of drugs		2.9 (2.6)	OD.	
No. NS-active of drugs		0.51 (0.68) ₃₄₄	stand	
Dementia	No	654 (86.2)		
	Yes	105 (13.8) ₃₄₅	ard	

deviation; n: number of individuals; SIMD: Scottish Index of Multiple Deprivation; *APOE*: apolipoprotein E gene; NS-active no. of drugs: number of drugs that act on the nervous system. Polygenic Risk Scores are not reported as they have mean 0 and sd 1 by default. *SIMD ranges from 4 (most deprived area) to 6505 (least deprived area).

3.2 Main analysis

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

The Cox PH models (unadjusted for death as competing risk) were run using dementia status as the time-to-event outcome variable and polypharmacy (number of drugs), Polygenic Risk Score (PRS) and their interaction (polypharmacy*PRS) as predictors. The models were adjusted for the covariates: APOE ε4 count, age, sex, BMI, SIMD index, comorbidities index, alcohol status, smoking status and 4 first genomic principal components. The polypharmacy predictor was either the "general" polypharmacy (total number of drugs) or the nervous system active polypharmacy (number of drugs acting on the nervous system). Cox PH models utilising, among others, age at baseline, sex, comorbidities index and socioeconomic variable as predictors of dementia in LBC1936 have been reported by Mullin et al (2023)⁴³. However, in this previous study motoric cognitive risk instead of polypharmacy / AD-PRS was the main predictor and Wave 3 was the baseline. Both here and in Mullin et al (2023)⁴³ these covariates had a non-significant effect on dementia risk. The results for the "general" polypharmacy Cox PH model are presented in the Figure 1 forest plot. Only the APOE ε4 allele count significantly increased – more than tripled - the risk of incident dementia over the 17.5-year follow-up (HR = 3.28; 95% CI: 2.38 - 4.54; p = 5.35×10^{-13}). Taking more drugs and having a high PRS both increased the risk of incident dementia, however, the effects were not significant. For number of drugs: HR = 1.04; 95% CI: 0.93 - 1.15; p = 0.517, and for PRS: HR = 1.15; 95% CI: 0.85 - 1.55; p = 0.376. The interaction effect between the number of drugs and PRS was in the direction of increased dementia risk above that of their separate effects but was non-significant (HR = 1.06; 95% CI: 0.98 - 1.15; p = 0.135).

All-cause Dementia ('General' poplypharmacy predictor)

Predictor		N	Events	Hazard ratio	HR (95% CI)	p-value
sex	male	391	53		Reference	
	female	368	52	-	1.05 (0.70, 1.57)	0.810
SIMD index		759		-	0.96 (0.77, 1.18)	0.680
APOE e4 count		759		· —	3.28 (2.38, 4.54)	<1e-04
age (years)		759			1.21 (0.94, 1.56)	0.147
ВМІ		759		•	1.04 (0.99, 1.08)	0.114
smoker	never	367	54		Reference	
	ex	328	43	-	1.00 (0.66, 1.53)	0.985
	current	64	8		1.72 (0.80, 3.68)	0.166
drinks alcohol	no	98	11	•	Reference	
	yes	661	94		1.23 (0.64, 2.36)	0.538
comorbidities idx		759		· =	0.96 (0.83, 1.12)	0.619
no. of drugs		759			1.04 (0.93, 1.15)	0.517
PRS		759		- ;■	1.15 (0.85, 1.55)	0.376
no. of drugs * PRS		759		L	1.06 (0.98, 1.15)	0.135

Figure 1: Forest plot showing the Cox PH model Hazard Ratios for each predictor's association with all-cause incident dementia. The "no. of drugs" predictor includes all drugs taken by an individual after data cleaning. HR for Genomic Principal Components are not shown for illustration purposes, but were included in the model. The forest plot was produced using the "forestmodel" R package. HR: Hazard Ratio; CI: Confidence Interval; PRS: Polygenic Risk Score; BMI: Body Mass Index; SIMD: Scottish Index of Multiple Deprivation.

Figure 2 presents the association results for the Cox PH model that includes the "nervous system active" polypharmacy predictor. The *APOE* ϵ 4 predictor is, again, a highly significant risk factor (HR = 3.36; 95% CI: 2.43 – 4.65); p = 2.63x10⁻¹³). This time, however, the number of nervous system active drugs significantly increased the follow-up dementia risk (HR = 1.37; 95% CI: 1.02 – 1.84; p = 0.035). The positive effect of the PRS was, now, also significant (HR = 1.42; 95% CI: 1.10 – 1.82; p = 0.006). The interaction between the number of

nervous system active drugs and the PRS, however, had a non-significant negative effect (HR = 0.95; 95% CI: 0.72 - 1.25; p = 0.707).

All-cause Dementia ('NS-active' polypharmacy predictor)

Predictor		N	Events	Hazard ratio	HR (95% CI)	p-value
sex	male	391	53		Reference	
	female	368	52		1.04 (0.70, 1.54)	0.857
SIMD index		759		-	0.95 (0.77, 1.18)	0.662
APOE e4 count		759		-	3.36 (2.43, 4.65)	<1e-04
age (years)		759		÷=-	1.19 (0.92, 1.54)	0.185
вмі		759		=	1.03 (0.99, 1.08)	0.158
smoker	never	367	54	•	Reference	
	ex	328	43	-	0.96 (0.63, 1.46)	0.856
	current	64	8		1.69 (0.79, 3.63)	0.178
drinks alcohol	no	98	11	•	Reference	
	yes	661	94	─	1.32 (0.69, 2.53)	0.399
comorbidities idx		759		•	0.96 (0.84, 1.09)	0.511
no. of NS-active drugs		759		⊢ ■	1.37 (1.02, 1.84)	0.035
PRS		759		-	1.42 (1.10, 1.82)	0.006
no. of NS-active drugs * PRS		759		-	0.95 (0.72, 1.25)	0.707

Figure 2: Forest plot showing the Cox PH model Hazard Ratios for each predictor's association with all-cause incident dementia. The "no. of NS-active drugs" predictor includes drugs acting on the nervous system taken by an individual. HR for Genomic Principal Components are not shown for illustration purposes, but were included in the model. The forest plot was produced using the "forestmodel" R package. HR: Hazard Ratio; CI: Confidence Interval; PRS: Polygenic Risk Score; BMI: Body Mass Index; SIMD: Scottish Index of Multiple Deprivation; NS-active: nervous systemactive.

The main results of the Fine – Grey competing risk regression models, adjusting for mortality as a competing risk of dementia, are presented in Figure 3. Models were run for both the "general" polypharmacy predictor and the "nervous systemactive" polypharmacy, and their interaction with PRS, adjusting for the full set of

covariates. Results for the full list of covariates are presented in Sup. Figure 4. For the "general" polypharmacy model, the results were similar to the unadjusted model, with only the APOE ε4 predictor having a significant effect (HR = 3.38; 95% CI: 2.46 - 4.66; p = 8.0×10^{-14}). "General" polypharmacy, PRS and their interaction all have small, positive, non-significant association with incident dementia, after adjusting for the risk of death (Figure 3, top). Regarding the "nervous system-active" polypharmacy model, the PRS genetic effect remained significant after accounting for death (HR = 1.42; 95% CI: 1.13 - 1.78; p = 0.0029), but the "nervous system-active" polypharmacy predictor marginally lost significance (HR = 1.27; 95% CI: 0.98 – 1.65; p = 0.068). The PRS * "ns-active" polypharmacy interaction was again nonsignificant (HR = 0.98; 95% CI: 0.78 -1.23; p = 0.86) (Figure 3, bottom). Because the interaction term was nonsignificant in both models, the mortality adjusted models were re-run omitting this term. Results showed that PRS had a significant positive effect on dementia risk in both general and NS-active polypharmacy models: HR(general) = 1.39; 95% CI: 1.15-1.67; p<0.001 and HR(NS-active) = 1.40; 95% CI: 1.16-1.69; p-value<0.001 respectively; and that polypharmacy effects were nonsignificant (Sup. Figure 5). Using AD instead of all-cause dementia as outcome did not meaningfully alter the results of either the "general" or the "nervous system-active" polypharmacy models (Sup. Figure 6 and Sup. Figure 7 for AD-specific Cox PH models and Sup. Figure 8 for AD-specific competing risk regression models).

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430




Figure 3: Forest plot showing the Competing Risk Regression models' Hazard Ratios for the association with all-cause incident dementia, adjusting for death as a competing risk. Only predictors of interest are shown here for illustration purposes, but the full set of predictors were included in the models. Upper figure shows the results for the model using the "general" polypharmacy variable (no. of drugs), whereas lower figure shows the results for the nervous-system active no. of drugs. The "Estimates" of the forest plot are Hazard Ratios (HR). CRR: Competing Risk Regression; UCI: Upper Confidence Interval; LCI: Lower Confidence Interval; PRS: Polygenic Risk Score; NS-active: nervous system-active. The forest plot was produced using the "forest" R package.

4 DISCUSSION

4.1 Interpretation of findings

This is the first study to assess the interaction between polypharmacy and dementia polygenic risk in shaping all-cause dementia risk. Here, higher polypharmacy exposure, higher polygenic risk (PRS), and their interaction were positively associated with increased dementia risk although only PRS was significant when main effects were considered. The positive direction of effect for the interaction between general polypharmacy and PRS is consistent with our hypothesis that the adverse effects of polypharmacy are modulated by adverse genetic effects which increases the risk of dementia over and above their separate effects. However, the nervous system acting polypharmacy interaction with genetic score had an almost zero non-significant effect. It is possible that the low variability of the predictor (only 9 people with 3 or more nervous system active medications) decreased accurate inferences. Adjusting for death as a competing risk did not substantially change results, indicating that mortality did not affect the association between predictors and dementia. This was unexpected, given the high number of deaths in the sample: 277 people in total and 220 people without dementia that could be potential patients otherwise. In these models, and omitting the nonsignificant polypharmacy x PRS interaction effect, the polygenic effect was significant in the hypothesised direction of increased dementia risk. General and NS-active polypharmacy main effects did not alter the risk of dementia, although the latter effect had a larger HR which approached significance indicating potential differences between types of medication used. In previous studies, PRS and polypharmacy have been often associated with dementia risk⁵¹, but they had not been modelled together. Our finding of non-significant polypharmacy effects

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

when controlling for AD polygenic risk might indicate that the previously reported polypharmacy effect on dementia is confounded by polygenic risk for the disease. However, this hypothesis may be difficult to prove using PRS. Here low correlation of AD-PRS with polypharmacy was observed (Pearson's r=0.041), and, overall, polygenic scores for complex diseases explain little variation of drug-related phenotypes⁵². APOE status is frequently used as a proxy covariate for genetic susceptibility in studies of polypharmacy effects on dementia^{28,53}, with polypharmacy regimes remaining significantly predictive of dementia risk after adjusting for APOE status²⁸. One study found that polypharmacy lost significance after adjusting for APOE in a population of Aboriginal Australians⁵⁴, although the polypharmacy effect size remained similar with its unadjusted value. Larger longitudinal studies of people with both low and high dementia polygenic risk and low and high polypharmacy use are needed to clarify the role of genetic confounding on polypharmacy effects. The APOE gene was the only other covariate that had a significant effect on dementia. This was expected, given its strong and well established role in dementia and AD pathogenesis⁸. Other well established risk factors did not have a significant effect on dementia: BMI, alcohol intake, smoking, and deprivation index, although their effects' direction was expected¹. Inadequate sample size is again a plausible explanation, coupled with restrictions of range in the variables stemming from selection bias in the LBC1936: participants are healthier and from higher socioeconomic status than the general population²⁹. In future, polypharmacy x polygenic interaction effects might be investigated with increased pathway specificity. For example, PRS calculated using only SNPs

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

pertaining to a certain biological pathway (e.g. synaptic processes)¹². Testing whether sub-categories of polypharmacy measurements, such as the nervous system specific polypharmacy predictor, mask the effects of nervous system related pathway-specific PRS could shed light on whether those pathways are modulated by specific drugs. An important caveat, however, is that the predictive ability of pathway-specific PRS are potentially smaller than the genome-wide PRS, so it would be necessary to use large sufficiently powered samples¹². Furthermore, when studying polypharmacy, a direct interpretation of associations with outcomes is difficult as confounding by indication may be present^{28,55}. This means that dementia may be caused not because of polypharmacy, but due to the comorbidities for which multiple drugs are taken. This can affect both the effects of polypharmacy exposure and the polypharmacy interaction with PRS. However, in the present study, the comorbidities index covariate was not significant and had negligible effect, indicating that the presence of comorbid health conditions did not affect dementia risk. This could be again arising due to small sample size, as per previous similar studies in LBC193643. It could be informative to include separate health conditions that are established dementia risk factors as covariates (e.g., depression, diabetes, and hypertension) and not as part of the comorbidities index covariate. Then, again, small sample size would not allow for the excessive use of covariates, due to the risk of overfitting.

4.2 Strengths and limitations

Several strengths can be identified for the present analysis. First, the high accuracy of the dementia ascertainment outcomes, being based on Electronic Health Records, clinical assessments and expert consensus⁴². This increases the

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

power to detect true associations with dementia risk, compared to non-curated dementia diagnoses. Secondly, the LBC1936 study design provides an appropriate dataset to study dementia, due to the older age of the participants (average of 69.5 years on baseline), extensive follow-up period (up to 17.5 years) and absence of dementia at baseline, allowing for the investigation of risk factors early on during disease development. Thirdly, LBC1936's thorough medication recording protocol, allowing the inclusion of both prescribed and over-the-counter medications in the polypharmacy predictors provides a more accurate picture of the medication state of the individuals. In other studies where polypharmacy is modelled, only prescribed drugs are included^{25,28}, which may underestimate the true polypharmacy burden. On the other hand, several limitations should be acknowledged. The major limitation of the study is the low sample size. Detecting genotype by environment interactions requires very large sample sizes, given their postulated small effect sizes³. Additionally, the definition of polypharmacy as the number of (systemic or nervous system acting) drugs taken at a certain time point (Wave 1 testing) is not optimal, as it lacks information on the duration of exposure and adherence to the medication. A better metric would be the number of daily drugs taken²¹ and the time period, however no such information was available. Electronic Health Records data may allow for such modelling. Finally, only baseline (Wave 1) information for all predictors was used (polypharmacy, covariates). Cumulatively incorporating the changes in the predictors over time until dementia diagnosis would improve the power to detect true associations. That is, using information from later waves to construct time-varying predictor variables in the Cox PH

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

models is a sensible future direction for better delineating polypharmacy trajectories.

5 CONCLUSIONS

In summary, in the present analysis it was hypothesised that the detrimental effect of polypharmacy on dementia is modulated by one's genetic profile, with high genetic risk exacerbating adverse polypharmacy effects. This interaction effect was not supported for general polypharmacy or nervous system acting polypharmacy. AD polygenic scores were associated with increased risk of dementia, and there was suggestion that nervous system active drugs had independent polypharmacy effects on dementia risk. Better characterising how polypharmacy exerts adverse effects on individuals with high or low dementia genetic risk may point towards supporting the case for de-prescribing inappropriate medications in older adults dependent on one's genetic risk towards dementia.

ACKNOWLEDGEMENTS

We are thankful to Dr. Sarah Harris and Dr. Jure Mur for the insightful discussions on various topics of the project and LBC1936, and to Paul Redmond and Dr. Gail Davies for guidance and assistance on data access.

This research was funded by the Legal & General Group (research grant to establish the independent Advanced Care Research Centre at University of

Edinburgh). The funder had no role in conduct of the study, interpretation or the decision to submit for publication. The views expressed are those of the authors and not necessarily those of Legal & General. The LBC1936 study is supported by the Biotechnology and Biological Sciences Research Council (BBSRC) and the ESRC (BB/W008793/1), Age UK (Disconnected Mind project), the Milton Damerel Trust, and the University of Edinburgh. SRC was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (221890/Z/20/Z). The Lothian Birth Cohort 1936 study acknowledges the financial support of NHS Research Scotland (NRS), through Edinburgh Clinical Research Facility. We gratefully acknowledge the contributions of the LBC1936 participants and members of the LBC1936 research team who collect and manage the LBC data.

All authors declare no competing interests.

REFERENCES

565

566

567

568

569

570

571

572

573

574

575

576

578

579

- Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *The Lancet*. 2024;404(10452):572-628.
 doi:10.1016/S0140-6736(24)01296-0
- Lourida I, Hannon E, Littlejohns TJ, et al. Association of Lifestyle and Genetic Risk With
 Incidence of Dementia. *JAMA*. 2019;322(5):430. doi:10.1001/jama.2019.9879
- Dunn AR, O'Connell KMS, Kaczorowski CC. Gene-by-environment interactions in Alzheimer's disease and Parkinson's disease. *Neuroscience & Biobehavioral Reviews*. 2019;103:73-80. doi:10.1016/j.neubiorev.2019.06.018
- 589 4. Reitz C, Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. *Biochemical Pharmacology*. 2014;88(4):640-651. doi:10.1016/j.bcp.2013.12.024
- 59. Bellenguez C. New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nature Genetics*. 2022;54.

593 6. Alzheimer Disease Genetics Consortium (ADGC), The European Alzheimer's Disease Initiative 594 (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium 595 (CHARGE), et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk 596 loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414-430. 597 doi:10.1038/s41588-019-0358-2 598 Gatz M, Reynolds CA, Fratiglioni L, et al. Role of Genes and Environments for Explaining 599 Alzheimer Disease. Arch Gen Psychiatry. 2006;63(2):168. doi:10.1001/archpsyc.63.2.168 600 Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms 601 and therapy. Nat Rev Neurol. 2013;9(2):106-118. doi:10.1038/nrneurol.2012.263 602 Gharbi-Meliani A, Dugravot A, Sabia S, et al. The association of APOE ε4 with cognitive 603 function over the adult life course and incidence of dementia: 20 years follow-up of the 604 Whitehall II study. Alz Res Therapy. 2021;13(1):5. doi:10.1186/s13195-020-00740-0 605 10. Ware EB, Faul JD, Mitchell CM, Bakulski KM. Considering the APOE locus in Alzheimer's 606 disease polygenic scores in the Health and Retirement Study: a longitudinal panel study. 607 BMC Med Genomics. 2020;13(1):164. doi:10.1186/s12920-020-00815-9 608 11. Leonenko G, Baker E, Stevenson-Hoare J, et al. Identifying individuals with high risk of 609 Alzheimer's disease using polygenic risk scores. Nat Commun. 2021;12(1):4506. 610 doi:10.1038/s41467-021-24082-z 611 12. Harrison JR, Mistry S, Muskett N, Escott-Price V. From Polygenic Scores to Precision 612 Medicine in Alzheimer's Disease: A Systematic Review. Brookes K, ed. JAD. 2020;74(4):1271-613 1283. doi:10.3233/JAD-191233 614 13. Seto M, Weiner RL, Dumitrescu L, Hohman TJ. Protective genes and pathways in Alzheimer's 615 disease: moving towards precision interventions. Mol Neurodegeneration. 2021;16(1):29. 616 doi:10.1186/s13024-021-00452-5 617 14. Choi SW, Mak TSH, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. 618 Nat Protoc. 2020;15(9):2759-2772. doi:10.1038/s41596-020-0353-1 619 15. Jin X, Shu C, Zeng Y, Liang L, Ji JS. Interaction of greenness and polygenic risk score of 620 Alzheimer's disease on risk of cognitive impairment. Science of The Total Environment. 621 2021;796:148767. doi:10.1016/j.scitotenv.2021.148767 622 16. Huang TL, Zandi PP, Tucker KL, et al. Benefits of fatty fish on dementia risk are stronger for 623 those without APOE ε4. Neurology. 2005;65(9):1409-1414. 624 doi:10.1212/01.wnl.0000183148.34197.2e 625 17. Licher S, Ahmad S, Karamujić-Čomić H, et al. Genetic predisposition, modifiable-risk-factor 626 profile and long-term dementia risk in the general population. Nat Med. 2019;25(9):1364-627 1369. doi:10.1038/s41591-019-0547-7 628 18. Kivipelto M, Rovio S, Ngandu T, et al. Apolipoprotein E 24 magnifies lifestyle risks for 629 dementia: a population-based study. Journal of Cellular and Molecular Medicine. 630 2008;12(6b):2762-2771. doi:10.1111/j.1582-4934.2008.00296.x

631 19. Solomon A, Turunen H, Ngandu T, et al. Effect of the Apolipoprotein E Genotype on 632 Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a 633 Randomized Clinical Trial. JAMA Neurol. 2018;75(4):462. doi:10.1001/jamaneurol.2017.4365 634 20. Rovio S, Kåreholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of 635 dementia and Alzheimer's disease. The Lancet Neurology. 2005;4(11):705-711. 636 doi:10.1016/S1474-4422(05)70198-8 637 21. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic 638 review of definitions. BMC Geriatr. 2017;17(1):230. doi:10.1186/s12877-017-0621-2 639 22. Esumi S, Ushio S, Zamami Y. Polypharmacy in Older Adults with Alzheimer's Disease. 640 Medicina. 2022;58(10):1445. doi:10.3390/medicina58101445 641 23. Fried TR, O'Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health Outcomes 642 Associated with Polypharmacy in Community-Dwelling Older Adults: A Systematic Review. J 643 Am Geriatr Soc. 2014;62(12):2261-2272. doi:10.1111/jgs.13153 644 24. Bushardt R. Polypharmacy: Misleading, but manageable. CIA. 2008; Volume 3:383-389. 645 doi:10.2147/CIA.S2468 646 25. Park HY, Park JW, Song HJ, Sohn HS, Kwon JW. The Association between Polypharmacy and 647 Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in 648 South Korea. Laks J, ed. PLoS ONE. 2017;12(1):e0169463. doi:10.1371/journal.pone.0169463 649 26. Clague F, Mercer SW, McLean G, Reynish E, Guthrie B. Comorbidity and polypharmacy in 650 people with dementia: insights from a large, population-based cross-sectional analysis of 651 primary care data. Age Ageing. Published online October 13, 2016:ageing;afw176v1. 652 doi:10.1093/ageing/afw176 653 27. Mueller C, Molokhia M, Perera G, et al. Polypharmacy in people with dementia: Associations 654 with adverse health outcomes. Experimental Gerontology. 2018;106:240-245. 655 doi:10.1016/j.exger.2018.02.011 656 28. Mur J, Russ TC, Cox SR, Marioni RE, Muniz-Terrera G. Association between anticholinergic 657 burden and dementia in UK Biobank. A&D Transl Res & Clin Interv. 2022;8(1):e12290. 658 doi:10.1002/trc2.12290 659 29. Taylor AM, Pattie A, Deary IJ. Cohort Profile Update: The Lothian Birth Cohorts of 1921 and 660 1936. International Journal of Epidemiology. 2018;47(4):1042-1042r. doi:10.1093/ije/dyy022 661 30. The Trend of Scottish Intelligence: A Comparison of the 1947 and 1932 Surveys of the 662 Intelligence of Eleven-Year-Old Pupils. University London Press; 1949:xxviii, 151. 663 31. Deary IJ, Whalley LJ, Starr JM. A lifetime of intelligence: Follow-up studies of the Scottish 664 mental surveys of 1932 and 1947. A lifetime of intelligence: Follow-up studies of the Scottish

32. Deary IJ, Gow AJ, Pattie A, Starr JM. Cohort Profile: The Lothian Birth Cohorts of 1921 and
 1936. International Journal of Epidemiology. 2012;41(6):1576-1584. doi:10.1093/ije/dyr197

mental surveys of 1932 and 1947. Published online 2009:xvi, 285-xvi, 285.

doi:10.1037/11857-000

665

33. Houlihan LM, Davies G, Tenesa A, et al. Common Variants of Large Effect in F12, KNG1, and

670 HRG Are Associated with Activated Partial Thromboplastin Time. *The American Journal of*

- 671 Human Genetics. 2010;86(4):626-631. doi:10.1016/j.ajhg.2010.02.016
- 34. the Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for genotype
- 673 imputation. *Nat Genet*. 2016;48(10):1279-1283. doi:10.1038/ng.3643
- 674 35. Weale ME. Quality Control for Genome-Wide Association Studies. In: Barnes MR, Breen G,
- eds. Genetic Variation. Vol 628. Methods in Molecular Biology. Humana Press; 2010:341-
- 676 372. doi:10.1007/978-1-60327-367-1 19
- 677 36. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK:
- rising to the challenge of larger and richer datasets. *GigaSci.* 2015;4(1):7.
- 679 doi:10.1186/s13742-015-0047-8
- 680 37. Purcell SM, Chang CC. PLINK v1.9. www.cog-genomics.org/plink/1.9/
- 681 38. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data.
- 682 *GigaScience*. 2019;8(7):giz082. doi:10.1093/gigascience/giz082
- 683 39. ATC/DDD Index 2023. WHO Collaborating Centre for Drug Statistics Methodology. Accessed
- January 7, 2023. https://www.whocc.no/atc_ddd_index/
- 685 40. British National Formulary (BNF). National Institute for Health and Care Excellence (NICE).
- Accessed January 7, 2023. https://bnf.nice.org.uk/
- 41. Uffelmann E, Huang QQ, Munung NS, et al. Genome-wide association studies. Nat Rev
- 688 Methods Primers. 2021;1(1):59. doi:10.1038/s43586-021-00056-9
- 689 42. Mullin DS, Stirland LE, Buchanan E, et al. Identifying dementia using medical data linkage in a
- longitudinal cohort study: Lothian Birth Cohort 1936. BMC Psychiatry. 2023;23(1):303.
- 691 doi:10.1186/s12888-023-04797-7
- 43. Mullin DS, Gadd D, Russ TC, Luciano M, Muniz-Terrera G. Motoric cognitive risk syndrome
- trajectories and incident dementia over 10 years. Cerebral Circulation Cognition and
- 694 *Behavior*. 2023;5:100178. doi:10.1016/j.cccb.2023.100178
- 695 44. International Classification of Diseases, Eleventh Revision (ICD-11), World Health
- Organization (WHO) 2019/2021. https://icd.who.int/en
- 697 45. Cox DR. Regression Models and Life-Tables. Journal of the Royal Statistical Society Series B
- 698 (Methodological). 1972;34(2):187-220.
- 699 46. Kalbfleisch JD, Schaubel DE. Fifty Years of the Cox Model. Annu Rev Stat Appl. 2023;10(1):1-
- 700 23. doi:10.1146/annurev-statistics-033021-014043
- 701 47. Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for
- 702 competing risk data. Statistics in Medicine. 2017;36(27):4391-4400. doi:10.1002/sim.7501
- 703 48. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk.
- Journal of the American Statistical Association. 1999;94(446):496-509.
- 705 doi:10.1080/01621459.1999.10474144

706 49. R Core Team. R: A language and environment for statistical computing. Published online 707 2022. https://www.R-project.org/ 708 50. Therneau T. A Package for Survival Analysis in R. https://CRAN.R-709 project.org/package=survival 710 51. Leelakanok N, D'Cunha RR. Association between polypharmacy and dementia - A systematic 711 review and metaanalysis. Aging & Mental Health. 2019;23(8):932-941. 712 doi:10.1080/13607863.2018.1468411 713 52. Simona A, Song W, Bates DW, Samer CF. Polygenic risk scores in pharmacogenomics: 714 opportunities and challenges—a mini review. Front Genet. 2023;14:1217049. 715 doi:10.3389/fgene.2023.1217049 716 53. Gray SL, Anderson ML, Dublin S, et al. Cumulative Use of Strong Anticholinergics and 717 Incident Dementia: A Prospective Cohort Study. JAMA Intern Med. 2015;175(3):401. 718 doi:10.1001/jamainternmed.2014.7663 719 54. Lavrencic LM, Delbaere K, Broe GA, et al. Dementia Incidence, APOE Genotype, and Risk 720 Factors for Cognitive Decline in Aboriginal Australians: A Longitudinal Cohort Study. 721 Neurology. 2022;98(11). doi:10.1212/WNL.000000000013295 722 55. Kyriacou DN, Lewis RJ. Confounding by Indication in Clinical Research. *JAMA*. 723 2016;316(17):1818. doi:10.1001/jama.2016.16435 724